samedi 28 juin 2014

Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said.

Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies

Aucun commentaire:

Enregistrer un commentaire